[go: up one dir, main page]

WO2000069841A3 - Benzofuranylaminoalcohols - Google Patents

Benzofuranylaminoalcohols Download PDF

Info

Publication number
WO2000069841A3
WO2000069841A3 PCT/EP2000/004015 EP0004015W WO0069841A3 WO 2000069841 A3 WO2000069841 A3 WO 2000069841A3 EP 0004015 W EP0004015 W EP 0004015W WO 0069841 A3 WO0069841 A3 WO 0069841A3
Authority
WO
WIPO (PCT)
Prior art keywords
benzofuranylaminoalcohols
medicaments
preparation
treatment
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/004015
Other languages
French (fr)
Other versions
WO2000069841A2 (en
Inventor
Gabriele Braeunlich
Mazen Es-Sayed
Ruediger Fischer
Burkhard Fugmann
Rolf Henning
Stephan Schneider
Michael Sperzel
Karl-Heinz Schlemmer
Graham Sturton
Mary Fitzgerald
Barbara Briggs
Arnel Conception
William Bullock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to AU45616/00A priority Critical patent/AU4561600A/en
Publication of WO2000069841A2 publication Critical patent/WO2000069841A2/en
Anticipated expiration legal-status Critical
Publication of WO2000069841A3 publication Critical patent/WO2000069841A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Benzofuranylaminoalcohols of general formula (I), process for their preparation and their use in medicaments, especially for the treatment of inflammatory processes.
PCT/EP2000/004015 1999-05-17 2000-05-04 Benzofuranylaminoalcohols Ceased WO2000069841A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU45616/00A AU4561600A (en) 1999-05-17 2000-05-04 Benzofuranylaminoalcohols

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9911453A GB2350110A (en) 1999-05-17 1999-05-17 Pharmaceutically active benzofurans
GB9911453.0 1999-05-17

Publications (2)

Publication Number Publication Date
WO2000069841A2 WO2000069841A2 (en) 2000-11-23
WO2000069841A3 true WO2000069841A3 (en) 2002-05-02

Family

ID=10853621

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/004015 Ceased WO2000069841A2 (en) 1999-05-17 2000-05-04 Benzofuranylaminoalcohols

Country Status (3)

Country Link
AU (1) AU4561600A (en)
GB (1) GB2350110A (en)
WO (1) WO2000069841A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153871B2 (en) 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
EP1478639A1 (en) 2002-02-22 2004-11-24 Bayer Pharmaceuticals Corporation Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
US7144885B2 (en) 2002-02-22 2006-12-05 Bayer Pharmaceuticals Corporation Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
RU2368604C2 (en) 2002-07-19 2009-09-27 Мемори Фармасьютиклз Корпорейшн Phosphodiestarase 4 inhibitors, containing n-substituted aniline and diphenylamine analogues
EP1549619B1 (en) * 2002-07-19 2009-01-21 Memory Pharmaceutical Corporation 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
CN100513397C (en) 2002-11-19 2009-07-15 记忆药物公司 Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors
WO2015166370A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146243A1 (en) * 1983-10-31 1985-06-26 Merck Frosst Canada Inc. Lipoxygenase inhibitors
EP0731099A1 (en) * 1995-03-06 1996-09-11 Bayer Ag N-(3-benzofuranyl)urea-derivatives
EP0779291A1 (en) * 1995-12-11 1997-06-18 Bayer Ag Heterocyclylcarbonyl substituted benzofuranyl-ureas
WO1998002440A1 (en) * 1996-07-12 1998-01-22 Bayer Aktiengesellschaft 3-ureido-pyridofurans and -pyridothiophenes for the treatment of inflammatory processes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4056626A (en) * 1971-05-13 1977-11-01 Kakenyaku Kako Co., Ltd. Pharmaceutical composition containing benzofuran derivative

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146243A1 (en) * 1983-10-31 1985-06-26 Merck Frosst Canada Inc. Lipoxygenase inhibitors
EP0731099A1 (en) * 1995-03-06 1996-09-11 Bayer Ag N-(3-benzofuranyl)urea-derivatives
EP0779291A1 (en) * 1995-12-11 1997-06-18 Bayer Ag Heterocyclylcarbonyl substituted benzofuranyl-ureas
WO1998002440A1 (en) * 1996-07-12 1998-01-22 Bayer Aktiengesellschaft 3-ureido-pyridofurans and -pyridothiophenes for the treatment of inflammatory processes

Also Published As

Publication number Publication date
AU4561600A (en) 2000-12-05
WO2000069841A2 (en) 2000-11-23
GB9911453D0 (en) 1999-07-14
GB2350110A (en) 2000-11-22

Similar Documents

Publication Publication Date Title
ZA200201511B (en) 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents.
MXPA02001497A (en) 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents.
HK1046527A1 (en) Adamantane derivatives
EP1352896A3 (en) Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
WO2002018327A3 (en) Guanidinobenzamides as mc4-r agonists
AU2002337047A1 (en) Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
HUP0401647A3 (en) Novel betha-phenyl-alpha-oxy propionic acid derivatives, processes for their preparation and their use in the preparation of pharmaceutically important compounds
AU763094C (en) Benzimidazoles, production thereof and use thereof as medicaments
WO2001028494A3 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
AU2001294228A1 (en) Benzimidazole compounds, process for producing the same and use thereof
AU6442900A (en) Aminocarbonyl-substituted benzimidazole derivatives, method for producing same and the use thereof as medicaments
WO2000069841A3 (en) Benzofuranylaminoalcohols
AU2011501A (en) Benzimidazoles, production thereof and the use thereof as antithrombotic
AU6866500A (en) Chromone derivatives, process for the preparation of the same and uses thereof
AU2001260110A1 (en) Novel LHRH-antagonists, Production and Use Thereof as Medicament
AU2001296173A1 (en) 3,8-diazabicyclo(3.2.1)octanes and their use in the treatment of cardiac arrhythmias
AU3290200A (en) Treatment agents for textiles, method of producing same and their use
AU2001277737A1 (en) Novel substance having physiological activity, process for producing the same, and use
WO2002070537A3 (en) Fusidic acid derivatives
AU2001252254A1 (en) 2,6-diamino-6-methyl-heptanoic acid and derivatives, process for the preparationthereof and use thereof
CA2387600A1 (en) Novel fusidic acid derivatives
AU2002241416A1 (en) Dermatological agent for the treatment of skin trauma, especially in burn conditions
AU2401401A (en) Migrastatin, process for producing the same and medicinal compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP